

Match Overview

1	Crossref 69 words Kazuhiisa Takeda, Yuji Tsurumaru, Yuji Yamamoto, Kentaro Araki et al. "Treatment of hepatocellular carcinoma with hepatic	3%
2	Internet 57 words crawled on 22-Sep-2020 research.kindai.ac.jp	3%
3	Crossref 24 words Michinori Hamaoka, Tsuyoshi Kobayashi, Shintaro Kuroda, Hiroshi Iwako et al. "Hepatectomy after down-staging of hepato	1%
4	Crossref 18 words Ali Gökyer, Ahmet Küçükarda, Sezin Sayın, Fatma Elif Usturalı Keskin, İrfan Çiçin. "Stage I colon cancer that spreads into a	1%
5	Internet 13 words crawled on 27-Sep-2020 business.starkvilledailynews.com	1%
6	Internet 12 words crawled on 07-Oct-2020 slideheaven.com	1%

Name of Journal: *World Journal of Hepatology*

Manuscript No. 58594

Manuscript Type: CASE REPORT

Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment: case report

Yokoo H *et al.* Surgery for recurrent HCC after lenvatinib

ABSTRACT

BACKGROUND

Lenvatinib has been shown to be non-inferior to sorafenib regarding prognosis and recurrence rate in ⁵ patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic chemotherapy. In patients treated with lenvatinib, 40% of cases achieved sufficient tumor reduction to make potential surgery possible. However, the outcomes of such surgery are unknown. We report a successful case of hepatic resection for recurrent HCC after lenvatinib treatment.



ALL

IMAGES

VIDEOS

34,600 Results

Any time ▾

Successful en bloc resection of recurrent hepatocellular ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333836>

Introduction. **Repeat hepatic resection** has previously been reported as the most **effective treatment for recurrence** of **intrahepatic carcinoma**. To the best of our knowledge, en bloc resection of **recurrent hepatocellular carcinoma** directly invading the abdominal wall has not been previously reported. **Case presentation.**

Cited by: 1

Author: Aijun Li, Bin Wu, Longjiu Cui, Mengchao Wu

Publish Year: 2015

Lenvatinib Combined With TACE to Prevent the Recurrence in ...

<https://clinicaltrials.gov/ct2/show/NCT03838796> ▾

Postoperative **recurrence** and metastasis of **hepatocellular carcinoma**(HCC) is the main problem during the **treatment**. Although with the development of medical science, some drugs have been found for the prevention and **treatment** of postoperative **recurrence** of HCC (such as postoperative application of interferon to prevent early tumor **recurrence**), but there is still no drug widely recognized.

Successful treatment of multiple lung metastases of ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668787>

Apr 14, 2009 · We **report** the **successful treatment** of multiple lung metastases **after hepatic resection** for **hepatocellular carcinoma** (HCC) with combined docetaxel, cisplatin (CDDP), and enteric-coated tegafur/uracil (UFT-E). A 68-year-old man was diagnosed with multiple lung metastases of HCC 7 mo **after** partial hepatectomy for HCC.

Cited by: 7

Author: Atsunori Tsuchiya, Michitaka Imai, Hiroteru...

Publish Year: 2009

ALL IMAGES VIDEOS MAPS NEWS SHOPPING

63,100 Results Any time ▾

Successful Resection in a Case of Hepatocellular Carcinoma ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328729>

Dec 28, 2018 · **Case report.** A 67 year-old male (body mass index of 23.9 kg/m²) presented with jaundice associated with pruritus for 1 month. There was no history of abdominal pain or weight loss. There was no previous history of regular alcohol intake, jaundice, ascites, gastrointestinal bleeding, chronic illnesses or medication intake, surgery or **hepatic** encephalopathy.

Author: Prakriti Gupta, Shashi Dhawan, Vivek ... **Publish Year:** 2018

Successful en bloc resection of recurrent hepatocellular ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333836>

Discussion. Tumor **recurrence** rates in HCC remain high, at 50% to 60% [3–15], and have even been reported to be over 80% []. The main cause of poor survival **after liver resection** is **recurrence**. Many authors have suggested that repeat **hepatic resection** might be the most effective **treatment** for intrahepatic **recurrence**, and the five-year survival rate following re-**resection** ranges from 31% to ...

Cited by: 1 **Author:** Aijun Li, Bin Wu, Longjiu Cui, Mengchao ...

Publish Year: 2015

Hepatic Resection as a Safe and Effective Treatment for ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602643>

INTRODUCTION. **Hepatocellular carcinoma** (HCC) is the third cause of **cancer**-related deaths, and its prevalence is expected to increase in coming decades. 1 HCC staging significantly affects **treatment** decisions and patient prognosis. Of the several staging systems proposed, the Barcelona Clinic **Liver Cancer** (BCLC) system 2 is the only one recommended by the American Association for the Study of ...

Cited by: 97 **Author:** Jian-Hong Zhong, A. Chapin Rodriguez, ...

Publish Year: 2015


Resection of recurrent hepatocellular carcinoma with ...

<https://wjso.biomedcentral.com/articles/10.1186/s12957-020-01914-8> ▾

Jun 22, 2020 · Shivathirthan N, Shimoda M, Kosuge T, Kato M, Kijima H, Sawada T, et al. **Recurrent**

Hepatocellular Carcinoma

Medical Condition



The most common form of liver cancer often seen in people with chronic liver diseases like cirrhosis.

- Rare (Fewer than 200,000 cases per year in US)
- May be preventable by vaccine
- Often requires lab test or imaging
- Treatment from medical professional advised
- Can last several months or years

Caused mainly due to the chronic infection of the liver or DNA mutation of the liver cells. Characterized by unexplained weight loss, upper abdominal pain and yellowing of the skin. Treatment options include hepatectomy, target drug delivery and the use of radiation to kill the cancerous cells.